Join Sagimet Biosciences (#SGMT) for a conference call and webcast on Thurs. June 13 at 12:30pm ET featuring Rohit Loomba, M.D., M.H.Sc., (MASLD Research Center, University of California San Diego), to discuss positive data from the FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. Attend: https://lnkd.in/g6v4DdAb
Sagimet Biosciences
Pharmaceutical Manufacturing
San Mateo, California 2,896 followers
About us
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors. For more information, please visit www.sagimet.com.
- Website
-
https://sagimet.com/
External link for Sagimet Biosciences
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- San Mateo, California
- Type
- Privately Held
Locations
-
Primary
Get directions
155 Bovet Rd
Suite 303
San Mateo, California 94402, US
Employees at Sagimet Biosciences
-
Eduardo Bruno Martins
Biotechnology & Pharmaceutical Clinical Development Executive
-
Nita Makhijani
Senior Accountant at Sagimet Biosciences
-
Paul Hoelscher
Retired Executive Vice President, Chief Financial Officer at Horizon
-
Gregory Duke
Senior Director of Research at 3-V Biosciences
Updates
-
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 Press Release: https://lnkd.in/gWFhiskW Presentation: https://lnkd.in/gZDt4Csw
-
-
Join Sagimet Biosciences (#SGMT) for a virtual investor and analyst day on Thurs. May 23 at 1:00pm ET featuring Scott L. Friedman, MD (Icahn School of Medicine at Mount Sinai), who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis #MASH. Register here: https://lnkd.in/g46Pa7Jy
-
-
Sagimet Biosciences’ first quarter 2024 financial results and corporate updates are now available: https://lnkd.in/ed5MKm_P #biotech #NASH #denifanstat #FASN #FASCINATE2 $SGMT
-
-
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer. Learn more here: https://lnkd.in/gp32f3Sn
-
-
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors. Learn more here: https://lnkd.in/gFavsWPF
-
Sagimet Biosciences’ fourth quarter and full year 2023 financial results and corporate updates are now available: https://lnkd.in/gUeJm35v
-
Next month, management will participate in two investor conferences. Learn more about how to access the webcasts and archived replays: https://lnkd.in/g2-U6nfm #biotech #NASH #denifanstat #TDCowenHealthCare #LeerinkPartners
-
-
Sagimet Biosciences announced pricing of a public offering of $112.5 M Series A common stock. Read more: https://lnkd.in/gJt5NUPy
-